Blue Jays pitching prospect Ricky Tiedemann listed as week-to-week after MRI
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Monthly Digital Subscription
$0 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*No charge for 4 weeks then price increases to the regular rate of $19.00 plus GST every four weeks. Offer available to new and qualified returning subscribers only. Cancel any time.
Monthly Digital Subscription
$4.75/week*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Billed as $19 plus GST every four weeks. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
*Your next subscription payment will increase by $1.00 and you will be charged $16.99 plus GST for four weeks. After four weeks, your payment will increase to $23.99 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 09/05/2023 (916 days ago), so information in it may no longer be current.
Toronto Blue Jays pitching prospect Ricky Tiedemann is listed as week-to-week with left biceps inflammation.
The team said Tuesday the injury was picked up in an MRI.
The 20-year-old Tiedemann left a start with double-A New Hampshire last Thursday after four innings with arm soreness.
Tiedemann has an 0-1 record with a 4.97 earned-run average over four starts for New Hampshire this season.
Baseball America has Tiedemann at No. 31 in its top 100 prospects list.
He was drafted in the third round of the 2021 MLB Amateur Draft out of Golden West College.
This report by The Canadian Press was first published May 9, 2023.